%0 Journal Article
%T Efficacy of Palmitoylethanolamide (Levagen+<sup>TM</sup>) Compared to Ibuprofen for Reducing Headache Pain Severity and Duration in Healthy Adults: A Double-Blind, Parallel, Randomized Clinical Trial
%A David Briskey
%A Phillippa Ebelt
%A Elizabeth Steels
%A Silma Subah
%A Nathasha Bogoda
%A Amanda Rao
%J Food and Nutrition Sciences
%P 690-701
%@ 2157-9458
%D 2022
%I Scientific Research Publishing
%R 10.4236/fns.2022.137050
%X <b><span style=\"font-family:&quot;\">Background:</span></b><span style=\"font-family:&quot;\"> Palmitoylethanolamide (PEA) has shown promise as an analgesic for those
with chronic pain pathologies. With recently increased bioavailability, PEA may
also be a treatment for acute pain presentations such as tension-type
headaches. <b>Aim:</b> To assess the efficacy of a bioavailable PEA formulation
(Levagen+<sup>TM</sup>) for reducing the severity and duration of acute
episodes of tension-type headaches when compared to a standard treatment,
nonsteroidal anti-inflammatory drug (NSAID) (the comparator). <b>Methods:</b> The study was a double-blind, randomized, single site, comparator controlled
clinical study, with the cohort consisting of otherwise healthy adults, aged <span>between 18 and 71, who experienced regular
tension-type headaches. 94 adults</span> experiencing headaches were randomised
to receive either PEA (n = 47) or Ibuprofen comparator (n = 47). Upon headache
onset, participants consumed their allocated product, recorded pain levels
using a visual analogue scale (VAS) and continued to log their pain scores at
30-minute intervals for up to 4-hours. <b>Results:</b> Eighty-six participants
(44 active treatment and 42 comparator) recorded at least one headache with a
total of 271 tension-type headaches recorded (120 active treatment and 151
comparator). Most headaches were reduced in both treatment arms by 2 hours and
almost all by 4 hours; 90% in the PEA group, and 97% in comparator group, p
&gt; 0.5. For moderate <span>at onset headaches,
the comparator group had a greater percentage of</span> pain-free events at
2-hours. However, the time taken to resolve severe headaches was significantly
lower in the PEA group than the comparator group (p &lt; 0.05). <b>Conclusions: </b>These results place PEA as a potential treatment option for tension-type
headaches.
%K PEA
%K Palmitoylethanolamide
%K Headaches
%K Levagen
%K LipiSperse
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=118715